PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients a Randomized, Open-label, Phase 3 Study
Phase of Trial: Phase III
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Pegaspargase (Primary) ; Dexamethasone; Gemcitabine; Methotrexate; Oxaliplatin; Thalidomide
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 25 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 06 Dec 2016 Interim results (n=110) assessing efficacy and toxicity presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 02 May 2014 New trial record